Abstract
Introduction
T lymphocytes recognize antigens via the heterodimeric T-cell receptor (TCR) molecule, which is noncovalently associated with the CD3 molecular complex. T lymphocytes are classified into two subsets, based on their TCR. Most T cells carry TCRs thay consist of an ab chain heterodimer. These T cells, referred to as ab T cells, can be further subdivided on the basis of the surface markers CD4 and CD8 [1] .
cd T cells are another type of T cell; these account for 2-5% of CD3
? peripheral blood T cells but constitute a dominant fraction of the T cells at other anatomical sites, such as the intestinal epithelia. Most cd T cells lack CD4 or CD8 antigens and hence display a ''double-negative'' phenotype, although a sizeable fraction express CD8. The absence of CD4 or CD8 expression on the majority of circulating cd T cells is well in line with the lack of MHC restriction in the antigen recognition of this T-cell subset [2] . In the blood of most healthy individuals, T cells expressing the Vd2 gene paired with a particular Vc chain (Vc9) account for 50 to [90% of the cd T-cell population. In contrast, intestinal intraepithelial cd T cells frequently express the Vd1 gene, which can associate with different Vc elements [2] . There are no major differences between ab and cd T cells with regard to effector functions. Thus, activated cd T cells have strong cytotoxic effector activity (using both death receptor/death ligand and cytolytic granule pathways), and produce various cytokines (frequently including tumor necrosis factor-a and IFN-c) [2] . However, cd TCRs seem to react to novel ligands that are not recognized by ab T cells, thus providing an essential additional pathway of local immunosurveillance with immediate relevance for tumor defense [2, 3] .
There is accumulating evidence that immune cells such as CD8
? T cells, NK cells, and dendritic cells show impaired function in cancer patients, resulting in tumor progression [4] . However, the function of cd T cells in cancer patients is unclear. The critical role of cd T cells in tumor defense implies that cd T-cell function is also impaired by cancer cells. In the current study, we therefore examined the frequency and function of cd T cells in peripheral blood, normal gastric mucosa, and cancer tissue. We also determined NKG2D expression on cd T cells in gastric cancer patients to show a mechanism that impairs cd T-cell function, because NKG2D is required by cd T cells to recognize and kill tumor cells.
Materials and methods

Patients and normal donors
Forty-seven patients (37 males and 10 females), treated at Tottori University Hospital and diagnosed with gastric cancer by pathologists, were enrolled in this study. None of the patients received radiotherapy, chemotherapy, or other medical interventions before blood donations. Informed consent for blood donations was obtained from all participants. Patient characteristics are shown in Table 1 . Healthy controls (n = 23; 16 males and 7 females) were age-matched (67.9 ± 11.0 years for controls; 69.6 ± 10.8 years for cancer patients), and each experiment was performed in parallel. The clinicopathological findings were determined according to the Japanese Classification of Gastric Carcinoma [5] .
Preparation of peripheral blood mononuclear cells (PBMCs)
Approximately 30 ml of peripheral blood was drawn from each control, and from each patient before surgery or chemotherapy; blood samples were prepared by centrifugation over a Ficoll-Paque (Pharmacia, Uppsala, Sweden) density gradient.
Isolation of tumor-infiltrating leukocytes
Freshly excised tumor tissues were minced and incubated in 1.5 mg/ml of collagenase D (Wako Pure Chemical Industries, Ltd., Osaka, Japan). Cell suspensions were then filtered through a mesh filter (BD Falcon, Franklin Lakes, NJ, USA). Tumor-infiltrating leukocytes (TILs) were available in 26 patients for the subset analysis of cd T cells and in 12 patients for the analysis of NKG2D expression and IFN-c production of Vd1 cd T cells. Since it is necessary to get large piece of tissue sample to have enough TILs for flow cytometry analysis, TILs from most early gastric cancer patients were not available for the analysis of NKG2D expression and IFN-c production of Vd1 cd T cells.
Flow cytometry analysis
Flow cytometry analysis was performed on a FACSCalibur TM (Becton Dickinson, Franklin Lakes, NJ, USA), using the following antibodies: anti-CD3-PE, anti-CD8-PE-Cy5, anti-CD3-PE-Cy5, anti-NKG2D-PE, anti-TCR cd-FITC (BD PharMingen, Franklin Lakes, NJ, USA), anti-Vd1-FITC, 
Statistical analysis
Either paired t tests or Mann-Whitney U tests were used to determine statistical differences between groups. Correlations were analyzed using the Spearman rank correlation coefficient. P \ 0.05 was considered significant. GraphPad Prism software (GraphPad Software, Inc., La Jolla, CA, USA) was used for statistical analyses.
Results
Prevalence of circulating cd T cells in gastric cancer patients
We first determined the frequency of each subtype of cd T cells in the peripheral blood of healthy controls and gastric cancer patients. Frequencies of Vd1, Vd2, and Vc9 cd T cells in healthy controls were 1.9 ± 1.3, 3.8 ± 3.4, and 4.1 ± 3.5%, respectively. Those in gastric cancer patients were 1.8 ± 1.5, 2.6 ± 3.5, and 2.7 ± 3.6%, respectively. The frequency of Vc9 cd T cells in gastric cancer patients was significantly lower than in healthy controls (P = 0.048). Furthermore, the frequency of Vd2 in gastric cancer patients tended to be lower than that in healthy controls (Fig. 1 ).
Frequency of cd T cells in the tissue of normal gastric mucosa and gastric cancer
We then investigated the frequencies of Vd1, Vd2, and Vc9 cd T cells in both normal gastric mucosa and gastric cancer tissue. The frequencies of Vd1, Vd2, and Vc9 cd T cells in normal gastric mucosa were 51.4 ± 15.3, 4.9 ± 4.6, and 2.7 ± 3.0%, respectively (Fig. 2a) . The frequencies of Vd1, Vd2, and Vc9 cd T cells in gastric cancer tissue were 41.4 ± 16.0, 3.2 ± 2.9, and 2.4 ± 2.5%, respectively (Fig. 2b) . The frequency of Vd1 cd T cells in gastric cancer tissue was significant lower than that in normal gastric mucosa (P = 0.015; Fig. 2c ). However, there were no statistically significant differences in the frequencies of Vd2 and Vc 9 cd T cells between normal gastric mucosa and gastric cancer tissue. On the other hand, the frequency of Vd1 cd T cells in gastric cancer tissue was 41.0 ± 8.8
and 41.6 ± 18.5% in early and advanced gastric cancer, respectively, and this difference was not significant (P = 0.98). Furthermore, the frequency of Vd1 cd T cells in gastric cancer tissue was 37.2 ± 11.1 and 45.0 ± 18.9% in stages I/II and III/IV, respectively, and this difference was not significant (P = 0.23).
NKG2D expression on Vd1 cd T cells decreased in gastric cancer tissue
Our data showed that cd T cells are abundant in gastric cancer tissue compared with peripheral blood. Moreover, because Vd1 cd T cells predominate among cd T cells in gastric cancer tissue, we investigated the function of such cells in gastric cancer patients. There was no statistical difference in IFN-c production from circulating Vd1 cd T cells between normal controls and cancer patients. On the other hand, Vd1 cd T cells obtained from gastric cancer tissue produced significantly less IFN-c than those obtained from normal gastric mucosa (P = 0.0097; Fig. 3 ). Since cd T cells require NKG2D to recognize and kill target cells, we examined NKG2D expression on Vd1 cd T cells in both normal gastric mucosa and gastric cancer tissue, and found it to be 60.0 ± 13.8 and 45.6 ± 10.1%, respectively; this difference was statistically significant (P = 0.0009; Fig. 4 ). With regard to the correlation between NKG2D expression and IFN-c production of Vd1 cd T cells, IFN-c was mainly produced by NKG2D-expressing Vd1 cd T cells (Fig. 5a ). Furthermore, we also found that the NKG2D expression and IFN-c production of Vd1 cd T cells in Fig. 1 Frequencies of Vd1, Vd2, and Vc9 cd T cells in peripheral blood from healthy control and gastric cancer patients. The frequency of Vc9 cd T cells in gastric cancer patients was significantly lower than that in healthy controls (P = 0.048); the frequency of Vd2 cells in gastric cancer patients also tended to be lower than that in healthy controls (P = 0.095) cd T cells in gastric cancer 435 gastric cancer tissue were significantly correlated (r = 0.75, P = 0.007; Fig. 5b) .
Discussion
In the current study, we demonstrated that Vd1 cd T cells predominate among cd T cells in both normal gastric mucosa and gastric cancer, whereas Vd2 and Vc9 cd T cells predominate in peripheral blood. The Vd1 cd T cells isolated from TILs of patients with colorectal cancer have been shown to lyse not only autologous but also various allogeneic epithelial tumor cells, indicating the importance of Vd1 cd T cells in tumor surveillance [6] . In the current study, we found that the frequency of Vd1 cd T cells in gastric cancer tissue was significantly less than in normal gastric mucosa. Furthermore, IFN-c production by Vd1 cd T cells in gastric cancer tissue was significantly less than that in normal gastric mucosa, indicating that Vd1 cd T cell function in gastric cancer tissue is impaired. On the other hand, the frequency of Vd1 cd T cells in the tissue of gastric cancer was not related to disease progression. Since we determined the frequency of Vd1 cd T cells in the tissue of gastric cancer, those cells are considered to have been already affected by cancer cells and their stromal cells, even in early gastric cancer.
The MHC class I chain-related molecules A and B (MICA and MICB) and the UL-16 binding proteins 1-3 (ULBP1-3) can be induced on epithelial cells by heat shock or oxidative stress, and are constitutively expressed to variable levels on many epithelial tumor cells and also on some leukemias and lymphomas. Such MICA/MICB-or ULBP-expressing tumor and lymphoma cells are killed by Vd1 cd T cells through recognition by NKG2D, which is the receptor for MICA, MICB, and ULBP [7, 8] . NKG2D is a type II C-lectin-like protein encoded by a gene located next to the NKG2A, NKG2C, and NKG2E genes within the natural killer (NK) gene complex on human chromosome 12p12-p13 and mouse chromosome 6 [9] . NKG2D is an activating cell surface receptor expressed by NK cells, cd T cells, some cytolytic CD8
? ab T cells, and NKT cells [10] [11] [12] [13] . In cancer patients, tumor-infiltrating and systemic NK cells and CD8
? T cells often express little NKG2D and are functionally compromised, indicating that decreased NKG2D expression on NK cells and CD8
? T cells is closely related to impaired function of those cells [14] . However, NKG2D expression on cd T cells and its relationship to impaired cd T-cell function in cancer patients remains unclear. In the current study, therefore, we studied NKG2D expression in Vd1 cd T cells to identify a mechanism responsible for impaired cd T-cell function in gastric cancer patients. NKG2D expression on Vd1 cd T cells is Fig. 2 Frequencies of Vd1, Vd2, and Vc9 cd T cells in both normal gastric mucosa (a) and gastric cancer tissue (b). c The frequency of Vd1 cd T cells in gastric cancer tissue was significantly less than that in normal gastric mucosa (P = 0.015). On the other hand, there were no statistically significant differences in the frequencies of Vd2 and Vc9 cd T cells between normal gastric mucosa and gastric cancer tissue significantly lower in gastric cancer tissue than in normal gastric mucosa. Furthermore, in gastric cancer tissue, NKG2D expression in Vd1 cd T cells significantly correlates with IFN-c production by Vd1 cd T cells, indicating that the impaired cd T-cell function observed in these tissues is due to decreased NKG2D expression on Vd1 cd T cells. The reason for this phenomenon remains unclear. We previously showed that NKG2D expression on CD8
? T cells is also downregulated; this decreased NKG2D expression correlates significantly with reduced IFN-c production by CD8
? T cells [15] . We have also shown that MICA expressed in gastric cancer cells is responsible for Immune cells with negative immune regulatory function at tumor sites have recently attracted considerable attention, since these cells are thought to play extremely important roles in the progression of tumors through the suppression of immune responses and induction of immune tolerance. The best-studied immunosuppressive cell population is that of CD4
? /CD25 ? regulatory T cells (Treg cells) [16] [17] [18] . Human Treg cells [19, 20] disable TAAspecific T-cell immunity [21, 22] . Increased numbers of Treg cells are correlated with poor survival in hepatocellular carcinoma patients [23] and ovarian cancer patients [19] . Treg cells also increase in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric cancer [24] . Furthermore, myeloid-derived suppressor cells [25, 26] 
and CD4
? /NKG2D ? T cells [27] can diminish immunity against cancer cells in cancer patients. These accumulating lines of evidence indicate that immunosuppressive cells play important roles in tumor progression. Notably, cd T cells also have an immune regulatory function. In this regard, Peng et al. [28] showed that a dominant Vd1 cd T cell population among lymphocytes infiltrating breast tumors was strongly able to suppress naive and effector T-cell responses, and to block the maturation and function of dendritic cells. Furthermore, they showed that these cells have suppressive activity in vivo through adoptive cotransfer experiments. Although the dominant subpopulation of cd T cells in gastric cancer tissue was also Vd1 cd T cells in the current study, the frequency of Vd1 cd T cells in the tissue of gastric cancer was significantly lower than that in normal gastric mucosa. Therefore, it is unlikely that the abundant Vd1 cd T cells seen in the current study have an immune regulatory function, although their immune regulatory activity was not determined in the current study.
In conclusion, our results show that the frequency of Vd1 cd T cells was decreased and that their function was impaired in gastric cancer tissue. Decreased NKG2D expression may be one of the mechanisms responsible for impaired Vd1 cd T-cell function. Development of specific treatments targeting NKG2D on Vd1 cd T cells may provide a clinical breakthrough for gastric cancer patients. 
Vd1
? cells. b IFN-c production of Vd1 cd T cells was significantly related to NKG2D expression on Vd1 cd T cells (r = 0.75, P = 0.007)
